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Abstract
Background: Pregnant women are at an increased risk for HIV infection due to unknown biological causes. Given
the strong effect of sex-hormones on the expression of immunomuodulatory factors, the central role of mucosal
immunity in HIV pathogenesis and the lack of previous studies, we here tested for differences in
immunomuodulatory factors in cervico-vaginal secretions between pregnant and non-pregnant women.
Methods: We compared concentrations of 39 immunomodulatory factors in cervicovaginal lavages (CVL) from 21
pregnant women to those of 24 non-pregnant healthy women from the US. We used Bonferroni correction to
correct for multiple testing and linear regression modeling to adjust for possible confounding by plasma cytokine
concentration, cervical ectopy, total protein concentration, and other possible confounders. Cervical ectopy was
determined by planimetry. Concentration of immunomodulatory factors were measured by a multiplex assay,
protein concentration by the Bradford Method.
Results: Twenty six (66%) of the 39 measured immunomodulatory factors were detectable in at least half of the
CVL samples included in the study. Pregnant women had threefold lower CVL concentration of CCL22 (geometric
mean: 29.6 pg/ml versus 89.7 pg/ml, p = 0.0011) than non-pregnant women. CVL CCL22 concentration additionally
correlated negatively with gestational age (Spearman correlation coefficient [RS]: -0.49, p = 0.0006). These
associations remained significant when corrected for multiple testing.
CCL22 concentration in CVL was positively correlated with age and negatively correlated with time since last coitus
and the size of cervical ectopy. However, none of these associations could explain the difference of CCL22
concentration between pregnant and non-pregnant women in this study, which remained significant in adjusted
analysis.
Conclusions: In this study population, pregnancy is associated with reduced concentrations of CCL22 in
cervicovaginal secretions. The role of CCL22 on HIV transmission should now be investigated in prospective
studies.
Background
Pregnant women are at higher risk of acquiring Human
Immunodeficiency Virus (HIV) infection compared to
non-pregnant women [1-4]. If HIV positive, pregnant
women may also transmit HIV more frequently to their
uninfected partner than non-pregnant women
(International Microbicides Conference 2010, abstract
#8). The increased susceptibility for HIV infection dur-
ing pregnancy is independent of sexual behavior and
likely due to biological causes [1]. However, the underly-
ing mechanisms for both the increased susceptibility and
infectivity are unknown.
Previous studies have shown that sex hormones influ-
ence female genital tract immunity [5] and a large body
of literature analyzed effects of proinflammatory cyto-
kine concentration in cervicovaginal secretions with
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any medium, provided the original work is properly cited.bacterial vaginosis and preterm birth [6]. However, com-
prehensive comparisons of cervicovaginal cytokine con-
centrations between pregnant and non-pregnant women
have to our knowledge not been conducted.
Given the central role of cytokines and other mucosal
immunomodulatory factors in HIV pathogenesis [7],
and the profound systemic changes during immunity
[8,9], we hypothesized that pregnancy may result in
shifts of the cervicovaginal cytokine profile that may
increase the risk of HIV infection. To explore this
hypothesis, we conducted a comprehensive analysis of
immunomuodulatory factors in samples collected from
pregnant and non-pregnant women.
Methods
Study population
The study enrolled 23 pregnant and 25 non-pregnant
women attending the Obstetrics and Gynecology clinic
at the University of Southern California Medical Center
in Los Angeles between February and April 2008.
Healthy women between 17 and 45 years of age were
invited to enroll in the study if they were: not on hor-
monal contraception in the last 6 months, had no
intrauterine device, did not report sexual intercourse
within the last 24 h and were not actively menstruating.
All women underwent a clinical examination. Women
with bacterial vaginosis or candidiasis were subsequently
excluded from the analysis, resulting in a final study
population of 21 pregnant and 24 non-pregnant women.
All women provided written consent and the study
was approved by the institutional review board at the
University of Southern California, Los Angeles, CA and
Children’s Hospital Los Angeles, CA.
Data and sample collection
Socio-demographic, obstetric and gynecological data
were collected by a structured questionnaire. A digital
picture of the cervix was taken with an inserted endo-
cervical wick (Tear-Flo™) serving as length standard.
After removal of the endocervical wicks, a CVL sample
was collected by bathing the cervical os in phosphate
buffered saline (PBS). Fluid in the vaginal vault was then
collected with a transfer pipette and stored on ice until
transported to the laboratory for processing within 4 h.
Blood was collected with ethylenediaminetetraacetic acid
(EDTA) as anticoagulant and cells were separated from
CVL sample and blood by low speed centrifugation.
Supernatants were frozen at -80°C until measurement.
Lab assays
Measurements of immunomodulatory factors were con-
ducted with the Milliplex™ Map Human Cytokine/Che-
mokine KIT for the measurement of 39 premixed
cytokines (Millipore, Billerica, MA) using the Luminex
technology (Luminex Corporation, Austin, TX) as speci-
fied in manufacturer’s instructions. Protein concentra-
tion in CVL was measured using the Quick-Start
Bradford Dye Reagent (Bio-Rad, Hercules, CA) accord-
ing to the manufacturer’s instructions. All samples were
assayed in duplicate and the mean between these mea-
surements used for all analysis.
Cervical ectopy
The size of the cervix as well as any visible endocervical
epithelium covering the ectocervix was determined by
planimetry and expressed in mm
2 using an image pro-
cessing program (Adobe Photoshop)[10,11]. The degree
of cervical ectopy was expressed as the percent of the
visible endocervix covering the ectocervix.
Statistical analysis
Concentrations outside of the range of the multiplex
a s s a yw e r ei m p u t e dw i t hav alue just below the lower
detection limit of the kit plus 2 standard deviations or
above the upper cut-off (10,000 pg/ml) of the assay. To
adjust for variation in the volume of phosphate buffered
saline (PBS) used during the CVL (10 or 12 ml) concen-
trations determined from samples with lower dilution
(10 ml) were divided by a factor of 1.2. Where appropri-
ate, variables were log10 transformed to approximate
normal distributions.
We used the chi-square test to compare categorical
variables, unless the expected cell counts below 5, in
which case we used Fisher’s exact test. The chi-square
trend test was used to compare ordered categorical vari-
ables, the Wilcoxon rank sum test for non-normally-dis-
tributed continuous variables, and the T-test for
normally distributed variables. Bonferroni correction
was used to correct for multiple testing. Pearson corre-
lation coefficient were calculated for normally distribu-
ted and Spearman correlation coefficient for non-
normally distributed variables.
Linear regression modeling was conducted to adjust
for confounding. Variables were retained in the final
model if they remained significantly associated with
log10-transformed CCL22 concentration or if they chan-
ged the effect estimate by more than 15%. Two missing
datapoints for the time since last coitus were imputed
with the population median of 7 days to retain all
women in the regression analysis. All statistical analyses
were performed using SAS software (Version 9.2, Cary,
NC).
Results
Characteristics of the study population
As expected, pregnant women more frequently
reported vaginal discharge and had more pronounced
cervical ectopy than non-pregnant women. Pregnant
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They, however, did not differ from non-pregnant
women in other socio-economic or gynecological vari-
ables (Table 1).
Twenty six (66%) of the 39 measured immunomodula-
tory factors were detectable in at least half of the CVL
samples included in the analysis. With the exception of
IL-1ra, none of immunomodulatory factors were fre-
quently above the detection limit of the assay (Table 2).
Pregnancy and immunomodulatory factors in CVL
CVL collected from pregnant women contained three-
fold lower concentrations of C-C motif chemokine 22
(CCL22; also known as macrophage-derived chemokine)
than CVL from non-pregnant women (mean ± standard
deviation [SD] of log10 pg CCL22 per ml 1.5 ± 0.4 ver-
sus 2.0 ± 0.5, p = 0.0011, geometric mean: 29.7 pg/ml vs
89.7 pg/ml). Pregnant women also had lower CVL con-
centrations of monocyte chemotactic protein-1 (MCP-1)
than non-pregnant women (mean ± SD of log10 pg per
ml among pregnant women: 1.6 ± 0.6 versus non-preg-
nant women 2.0 ± 0.7, p = 0.03; geometric mean: 41.1
pg/ml versus 111.4 pg/ml); however, only the difference
in CCL22 remained significant when adjusted for multi-
ple testing (p < 0.0013).
The difference in CVL CCL22 concentration between
pregnant and non-pregnant women strengthened
slightly when pregnant women were restricted to those
in their third trimester (n = 13) (mean ± standard devia-
tion [SD] of log10 pg CCL22 per ml 1.4 ± 0.4 versus 2.0
± 0.5, p = 0.0011, geometric mean: 23.6 pg/ml vs 89.7
pg/ml). There additionally was a strong negative correla-
tion between gestational age and CCL22 concentration
in CVL (Spearman correlation coefficient [RS]: -0.49, p
= 0.0006) when analyzed in the whole population
assigning a gestational age of “0” to non-pregnant
women (Figure 1). There was, however, no significant
association of CCL22 concentration with gestational age
when restricted to pregnant women (RS = -0.21, p =
0.34)
Correlation of CVL CCL22 concentration with other
immunomodulatory factors
As listed in Table 3, the concentration of CCLL22 con-
centration correlated or tended to correlated with that
of Eotaxin, Fractalkine, GM-CSF, GRO, IL-17, IL-9, IP-
10, MCP-1, MCP-3, TGFa,T N F b and VEGF in CVL.
There was, however, no correlation with the total pro-
tein concentration in CVL (RS =0 . 1 0 ;p=0 . 5 1 )o rw i t h
plasma CCL22 concentration (RS = 0.06, p = 0.69).
Can the difference in CVL CCL22 concentration between
pregnant and non-pregnant women be explained by
other factors?
To test whether underlying differences between preg-
nant and non-pregnant women may have caused the dif-
ference in CCL22 concentration, we conducted linear
regression modeling adjusting for possible confounders.
In univariate analysis, age, time since last coitus and the
size of cervical ectopy were additionally associated with
CCL22 concentration in CVL (Table 4). When adjusted
for age and time since last coitus, the association
between pregnancy and CCL22 concentrations remained
strong. None of the other variables shown in Table 1,
including cervical ectopy or vaginal discharge, remained
significantly associated with the CCL22 concentration or
appreciably changed the effect estimate when addition-
ally included in the model. The results are similar, when
Table 1 Characteristics of 21 pregnant and 24 non-pregnant women included in the analysis
Variable Pregnant women Non-pregnant women p-value
Socio-demographic variables
Age [mean (STD)] 27.7 ± 6.0 33.8 ± 7.0 0.003
Hispanic [n (%)] 19 (90) 23 (96) 0.59
Obstetric/gynecological variables
Gestational age [median weeks (IQR)] 28 (22-32) /
Parity [n (%)]:
0 previous births 9 (43) 6 (26) 0.35
1-2 previous births 6 (29) 9 (39)
3+ previous births 6 (29) 8 (35)
Days since last coitus [median (IQR)] 7 (4, 15) 7 (3, 15) 0.63
Vaginal discharge [n (%)] 14 (67) 8 (33) 0.03
Vaginal bleeding during sample collection [n (%)] 9 (43) 5 (21) 0.11
Cervical ectopy [n (%)] 14 (67) 10 (42) 0.09
Size of ectopy among women with ectopy [median % (IQR)] 47 (32, 54) 17 (8, 26) 0.008
CVL protein concentration [median μg/ml (IQR)] 0.15 (0.07, 0.29) 0.10 (0.06, 0.18) 0.24
STD = standard deviation; IQR = interquartile range. Numbers may be slightly lower than the total due to missing data.
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model or when the CCL22 concentration is expressed as
ratio of CCL22 to total protein in CVL to adjust for
possible variation during the sample collection.
Discussion
Among this group of healthy American women, we
found threefold lower concentration of CCL22 in CVL
samples from pregnant women than in those from non-
Table 2 Concentrations of immunomodulatory factors in CVL of 21 pregnant and 24 non-pregnant women from Los
Angeles
Total Pregnant Non-pregnant p-
value
Factor n
detectable*
Median (IQR) or geometric mean
[pg/ml]
#
Median (IQR) or geometric mean
[pg/ml]
#
Median (IQR) or geometric mean
[pg/ml]
#
EGF 45 90.2 (75.1, 128.8) 89.0 102.6 0.33
Eotaxin 45 38.9 (28.5, 47.2) 36.1 40.7 0.43
FGF-2 34 11.1 (7.7, 21.5) 9.6 (< 3.2; 18.5) 8.9 (< 3.2; 17.8) 0.95
Flt-3
ligand
2 184.3 (14.9, 353.6) < 4.6 (< 4.6; < 4.6) < 4.6 (< 4.6; < 4.6) 0.97
Fractalkine 36 132.4(66.2, 293.6) 106.7(29.7; 171.7) 95.0 (11.2; 222.4) 0.92
G-CSF 45 383.4 (131.5, 741.6) 307.9 249.5 0.66
GM-CSF 36 77.8 (44.8, 137.3) 60.8 (18.8; 105.1) 64.6 (26.4; 123.5) 0.33
GRO 45 1,368.1 (756.0, 1,984.4) 1,175.8 (472.4; 2,328.0) 1,487.0 (1,109.0; 1,859.5) 0.49
IFNg 42 2.0 (1.0, 3.8) 1.6 2.2 0.39
IFNa2 4 213.5 (93.1, 316.8) < 40.6 (< 40.6; 40. < 6) < 40.6 (< 40.6; < 40. 6) 0.98
IL-10 17 3.8 (1.1, 30.4) < 0.5 (< 0.5; 1.3) < 0.5 (< 0.5; 1.1) 0.90
IL-12p40 42 93.3 (58.2, 180.3) 105.7 86.2 0.48
IL-12p70 24 4.7 (2.5, 13.6) 0.9 (< 0.8; 3.5) 1.8 (< 0.8; 5.5) 0.49
IL-13 12 5.0 (1.9, 20.4) < 0.9 (< 0.9; < 0.9) < 0.9 (< 0.9; 1.7) 0.59
IL-15 18 4.0 (1.1, 5.6) < 0.7 (< 0.7; 1.1) < 0.7 (< 0.7; 4.0) 0.70
IL-17 45 3.0 (2.0, 4.2) 2.6 3.2 0.39
IL-1a 45 664.2 (278.9, 1,526.3) 812.8 502.5 0.15
IL-1b 28 30.4 (7.6, 49.8) 6.8 (< 0.7; 37.6) 6.9 (< 0.7; 40.5) 0.97
IL-1ra 45 > 10,000 (> 10,000, > 10,000) > 10,000 (> 10,000, > 10,000) > 10,000 (> 10,000, > 10,000) 0.37
IL-2 16 9.3 (1.6, 18.6) < 0.6 (< 0.6; 6.6) < 0.6 (< 0.6; 0.8) 0.15
IL-3 43 144.0 (69.8, 187.2) 155.5 (110.2; 187.2) 142.2 (58.5; 171.0) 0.65
IL-4 1 27.9 < 1.1 (< 1.1; < 1.1) < 1.1 (< 1.1; < 1.1) 0.37
IL-5 12 0.1 (0.1, 0.3) < 0.1 (< 0.1; < 0.1) < 0.1 (< 0.1; 0.1) 0.51
IL-6 38 42.2 (22.1, 94.9) 34.1 (5.6; 91.7) 29.0 (9.1; 65.9) 1.00
IL-7 15 28.8 (7.6, 39.4) < 4.0 (< 4.0; 17.1) < 4.0 (< 4.0; 6.7) 0.74
IL-8 45 405.8 (254.3, 958.6) 526.0 429.4 0.52
IL-9 41 25.9 (6.8, 49.0) 11.6 18.4 0.28
IP-10 45 112.6 (40.5, 263.7) 97.7 144.2 0.29
MCP-1 44 79.3 (22.2, 208.6) 41.1 111.4 0.03
MCP-3 3 14.2 (6.0, 20.2) < 3.7 (< 3.7; < 3.7) < 3.7 (< 3.7; < 3.7) 0.62
CCL22 42 63.2 (25.9, 131.9) 29.7 89.7 0.001
MIP-1a 44 62.0 (36.6, 86.0) 54.3 57.5 0.79
MIP-1b 35 55.2 (30.9, 108.9) 35.3 (9.5; 69.9) 46.8 (22.0; 91.5) 0.52
sCD40L 8 52.0 (24.5, 98.8) < 9.0 (< 9.0; < 9.0) < 9.0 (< 9.0; < 9.0) 0.90
sIL-2Ra 6 22.9 (15.0, 27.5) < 7.7 (< 7.7; < 7.7) < 7.7 (< 7.7; < 7.7) 0.60
TGFa 38 14.4 (5.9, 24.0) 9.5 (2.8; 26.5) 12.9 (3.8; 17.3) 0.72
TNFa 43 0.8 (0.5, 2.8) 0.8 (0.5; 2.4) 0.9 (0.5; 2.5) 0.84
TNFb 13 7.1 (5.0, 13.6) < 3.4 (< 3.4; 4.3) < 3.4 (< 3.4; 4.7) 1.00
VEGF 43 56.2 (37.1, 102.6) 53.3 73.9 0.29
IQR = interquartile range
* number of samples with concentrations above the detection limit of the kit plus 2 standard deviations as provided by the manufacturer;
# undetectable samples were imputed with a values just below the cut off, geometric means (a single number) are shown for variables normally distributed on
the log scale, median and interquartile range are shown for non-normally distributed variables
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when corrected for multiple testing or in adjusted analy-
sis, suggesting that pregnancy may result in reduced
concentration of cervicovaginal CCL22.
The strength of this study lies in the large number of
analyzed cytokines and immunomodulatory factors
among healthy women. To our knowledge, this is the
most comprehensive analysis of these factors in CVL of
pregnant and non-pregnant women. In contrast to at
least some previous studies [12-15], we did not detect
differences in proinflammatory cytokines between preg-
nant and non-pregnant women. This could be explained
by the sample size, the exclusion of women with clinical
bacterial vaginosis, the relatively early collection of sam-
ples or fluctuations of these cytokines throughout preg-
nancy. We are however the first study that tested
CCL22 concentrations in CVL.
CCL22 has previously been detected in other mucosal
sites including the intestine [16], the lung [17] and the
endometrium [18] as well as in vaginal tissue in mice
[19], thus its presence in vaginal tissues among humans
seems plausible.
Previous studies have described fluctuations of
C C L 2 2e x p r e s s i o ni ne n d o m e t r i u md u r i n gt h em e n -
strual cycle and increases in the same tissue during
early pregnancy [20], suggesting a control by sex hor-
mones. While it is unclear, what caused the decreased
CCL22 concentrations among pregnant women in our
study, progesterone has been shown to suppress the
NF-B transcription factor [21], which is an activator
of CCL22 expression [22]. It is therefore possible that
increased progesterone concentrations directly result in
reduced CCL22 expression, which should be tested in
vitro. In addition, CCL22 in our analysis was asso-
ciated with a number of immunomodulatory factors,
especially Ip10 and MCP-1. It was also increased
shortly after coitus. Thus it is likely that there are a
number of other physiological and immunological
mechanisms that also influence CCL22 concentrations
in CVL [23].
Intriguingly, CCL22 has been implied in the HIV
pathogenesis in several ways. CCL22 is a T-helper cell
type (TH) 2 cytokine that is highly expressed in macro-
phages and dendritic cells of the monocyte line [17] as
well as in activated T-cells [24]. It is a strong chemoat-
tractant for leukocytes expressing the CCR4 receptor
[23] and has been suggested to be a key regulator of
innate immunity in mice [25]. In at least some in vitro
studies, CCL22 has been suggested to have HIV sup-
pressive effects [26-29]. Such mechanisms could explain
the increased risk of HIV infection with decreased
CCL22 concentration. However, at least one other study
suggested that CCL22 is secreted by CD16+ monocyte-
derived macrophages to activate resting T-cells for HIV
infection [30] and may therefore also increase the risk
of HIV infection in certain situation. Thus further analy-
sis of the effects of CCL22 on mucosal cytokine concen-
tration is required.
As in all statistical analysis, we cannot exclude that
differences in CVL concentrations of CCL22 are caused
by chance. However, given the strong difference
observed here, its possible regulation by sex hormones
and its possible implication in HIV pathogens, a role of
CCL22 in mediating a protection against HIV at the
female genital mucosa seems plausible and should be
investigated further.
Figure 1 Scatter plot of CCL22 concentration in cervicovaginal
lavages with gestational age among 21 pregnant and 24 non-
pregnant women. Non-pregnant women were assigned a
gestational age of 0 weeks.
Table 3 Immunomodulatory factors associated with
CCL22 in CVL
Factor Correlation Coefficient p-value
Eotaxin RP = 0.38 0.01
Fractalkine RS = 0.26 0.09
GM-CSF RS = 0.43 0.003
GRO RS = 0.38 0.01
IL-17 RP = 0.33 0.03
IL-9 RP = 0.28 0.06
IP-10 RP = 0.61 < .0001
MCP-1 RP = 0.57 < .0001
MCP-3 RS = 0.25 0.10
TGFa RS = 0.29 0.05
TNFb RS = 0.26 0.08
VEGF RP = 0.41 0.005
All concentrations were in log10 pg/ml. RP = Pearson correlation coefficient; RS
= Spearman correlation coefficient
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In this cohort, pregnancy is associated with reduced
CCL22 concentration in cervicovaginal secretion, which
may influence the risk of HIV infection.
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